SOPHIA ANTIPOLIS, France, May 6 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S. phase 2 study, conducted by its partner Pfizer Inc, which compared the safety and efficacy of various doses of PF-03187207 to Xalatan(R) (latanoprost) 0.005% in patients with primary open-angle glaucoma and ocular hypertension. The higher doses of PF-03187207 demonstrated a clinically significant reduction in diurnal intraocular pressure (IOP) from baseline and the highest dose showed consistently more IOP lowering than Xalatan(R) 0.005%, at all study visits and at all individual time points, suggesting a beneficial effect of nitric oxide donation. PF-03187207 is a nitric oxide-donating prostaglandin analog, which is covered by the companies' August 2004 agreement. On the primary endpoint at 28 days, PF-03187207 showed a 12% improvement over Xalatan(R) 0.005% which did not reach statistical significance. However, a statistically significant advantage over Xalatan(R) 0.005% was observed on a number of secondary endpoints (p